VIPR1

Across TCGA pan-cancer cohorts, VIPR1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated VIPR1 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher VIPR1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated VIPR1 expression acts as an unfavorable survival marker.

ACC and SKCM are the cancer types where VIPR1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

VIPR1–ACC (DFS)

Open the ACC breakdown →